You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Polycythaemia Vera: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Ruth Stuckey.

Polycythaemia Vera (PV) is a

BCR-ABL1

-negative MPN characterized by the clonal proliferation of hematopoietic progenitor cells, resulting in an increased production of morphologically normal red blood cells, white blood cells and platelets, although erythrocytosis most often predominates. The disorder is most common in those aged 50–70 years, with an incidence that increases with older age. Patients diagnosed with PV have a shorter survival compared to the age-matched general population, with a median survival of 13.5 years, due to an increased predisposition for thrombosis as well as transformation to myelofibrosis (post-PV myelofibrosis, estimated to occur in 10% of patients with PV) or acute myeloid leukaemia (AML, estimated to occur in 15% of patients with PV).

  • myeloproliferative neoplasms
  • molecular analysis
  • polycythaemia vera
Please wait, diff process is still running!

References

  1. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. In World Health Organization Classification of Tumours, 4th ed.; Bosman, F.T., Jaffe, E.S., Lakhani, S.R., Ohgaki, H., Eds.; IARC: Lyon, France, 2008; Volume 2.
  2. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405.
  3. Raedler, L.A. Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable. Am. Health Drug Benefits 2014, 7, S36–S47.
  4. Vannucchi, A.M.; Barbui, T.; Cervantes, F.; Harrison, C.; Kiladjian, J.J.; Kröger, N.; Thiele, J.; Buske, C.; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015, 26, 85–99.
  5. Nangalia, J.; Grinfeld, J.; Green, A.R. Pathogenesis of Myeloproliferative Disorders. Annu Rev. Pathol Mech Dis. 2016, 11, 101–126.
  6. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365, 1054–1061.
  7. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352, 1779–1790.
  8. Passamonti, F.; Rumi, E.; Pietra, D.; Elena, C.; Boveri, E.; Arcaini, L.; Roncoroni, E.; Astori, C.; Merli, M.; Boggi, S.; et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24, 1574–1579.
  9. Langabeer, S.E.; Andrikovics, H.; Asp, J.; Bellosillo, B.; Carillo, S.; Haslam, K.; Kjaer, L.; Lippert, E.; Mansier, O.; Oppliger Leibundgut, E.; et al. Molecular diagnostics of myeloproliferative neoplasms. Eur. J. Haematol. 2015, 95, 270–279.
  10. Broséus, J.; Park, J.H.; Carillo, S.; Hermouet, S.; Girodon, F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014, 124, 3964–3966.
  11. Belcic Mikic, T.; Pajic, T.; Sever, M. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Sci. Rep. 2019, 9, 19838.
  12. Gong, J.Z.; Cook, J.R.; Greiner, T.C.; Hedvat, C.; Hill, C.E.; Lim, M.S.; Longtine, J.A.; Sabath, D.; Wang, Y.L.; Association for Molecular Pathology. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: A report of the Association for Molecular Pathology. J. Mol. Diagn 2013, 15, 733–744.
  13. Passamonti, F.; Elena, C.; Schnittger, S.; Skoda, R.C.; Green, A.R.; Girodon, F.; Kiladjian, J.J.; McMullin, M.F.; Ruggeri, M.; Besses, C.; et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117, 2813–2816.
  14. Li, S.; Kralovics, R.; De Libero, G.; Theocharides, A.; Gisslinger, H.; Skoda, R.C. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111, 3863–3866.
  15. Scott, L.M.; Tong, W.; Levine, R.L.; Scott, M.A.; Beer, P.A.; Stratton, M.R.; Futreal, P.A.; Erber, W.N.; McMullin, M.F.; Harrison, C.N.; et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356, 459–468.
  16. Pietra, D.; Li, S.; Brisci, A.; Passamonti, F.; Rumi, E.; Theocharides, A.; Ferrari, M.; Gisslinger, H.; Kralovics, R.; Cremonesi, L.; et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111, 1686–1689.
  17. Grisouard, J.; Li, S.; Kubovcakova, L.; Rao, T.N.; Meyer, S.C.; Lundberg, P.; Hao-Shen, H.; Romanet, V.; Murakami, M.; Radimerski, T.; et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood 2016, 128, 839–851.
  18. Barbui, T.; Tefferi, A.; Vannucchi, A.M.; Passamonti, F.; Silver, R.T.; Hoffman, R.; Verstovsek, S.; Mesa, R.; Kiladjian, J.J.; Hehlmann, R.; et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia 2018, 32, 1057–1069.
  19. Jovanovic, J.V.; Ivey, A.; Vannucchi, A.M.; Lippert, E.; Oppliger Leibundgut, E.; Cassinat, B.; Pallisgaard, N.; Maroc, N.; Hermouet, S.; Nickless, G.; et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013, 2, 2032–2039.
  20. Link-Lenczowska, D.; Pallisgaard, N.; Cordua, S.; Zawada, M.; Czekalska, S.; Krochmalczyk, D.; Kanduła, Z.; Sacha, T. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. Ann. Hematol. 2018, 97, 2299–2308.
  21. Coccaro, N.; Tota, G.; Anelli, L.; Zagaria, A.; Specchia, G.; Albano, F. Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. Int. J. Mol. Sci. 2020, 21, 3141.
  22. Ma, W.; Kantarjian, H.; Zhang, X.; Yeh, C.H.; Zhang, Z.J.; Verstovsek, S.; Albitar, M. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J. Mol. Diagn 2009, 11, 49–53.
  23. Maslah, N.; Verger, E.; Schlageter, M.H.; Miclea, J.M.; Kiladjian, J.J.; Giraudier, S.; Chomienne, C.; Cassinat, B. Next-generation sequencing for JAK2 mutation testing: Advantages and pitfalls. Ann. Hematol. 2018, 98, 111–118.
  24. Singh, R.R. Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications. J. Mol. Diagn 2020, 22, 994–1007.
  25. Hocking, J.; Mithraprabhu, S.; Kalff, A.; Spencer, A. Liquid biopsies for liquid tumors: Emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol. Med. 2016, 13, 215–225.
  26. Garcia-Gisbert, N.; Fernández-Ibarrondo, L.; Fernández-Rodríguez, C.; Gibert, J.; Andrade-Campos, M.; Arenillas, L.; Camacho, L.; Angona, A.; Longarón, R.; Salar, A.; et al. Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms. Br. J. Haematol. 2020.
  27. Lasho, T.L.; Pardanani, A.; Tefferi, A. LNK mutations in JAK2 mutation-negative erythrocytosis. N. Engl. J. Med. 2010, 363, 1189–1190.
  28. Oh, S.T.; Simonds, E.F.; Jones, C.; Hale, M.B.; Goltsev, Y.; Gibbs, K.D., Jr.; Merker, J.D.; Zehnder, J.L.; Nolan, G.P.; Gotlib, J. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116, 988–992.
  29. Ema, H.; Sudo, K.; Seita, J.; Matsubara, A.; Morita, Y.; Osawa, M.; Takatsu, K.; Takaki, S.; Nakauchi, H. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev. Cell 2005, 8, 907–914.
  30. Bersenev, A.; Wu, C.; Balcerek, J.; Tong, W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest 2008, 118, 2832–2844.
  31. Guglielmelli, P.; Pietra, D.; Pane, F.; Pancrazzi, A.; Cazzola, M.; Vannucchi, A.M.; Tura, S.; Barosi, G. Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology. Leuk Res. 2017, 58, 63–72.
  32. Chen, Y.; Fang, F.; Hu, Y.; Liu, Q.; Bu, D.; Tan, M.; Wu, L.; Zhu, P. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. PLoS ONE 2016, 11, e0154183.
  33. Parganas, E.; Wang, D.; Stravopodis, D.; Topham, D.J.; Marine, J.C.; Teglund, S.; Vanin, E.F.; Bodner, S.; Colamonici, O.R.; van Deursen, J.M.; et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93, 385–395.
  34. Quelle, F.W.; Wang, J.; Feng, J.; Wang, D.; Cleveland, J.L.; Ihle, J.N.; Zambetti, G.P. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev. 1998, 12, 1099–1107.
  35. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387–397.
  36. Kralovics, R.; Guan, Y.; Prchal, J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 2002, 30, 229–236.
  37. Jamieson, C.H.; Gotlib, J.; Durocher, J.A.; Chao, M.P.; Mariappan, M.R.; Lay, M.; Jones, C.; Zehnder, J.L.; Lilleberg, S.L.; Weissman, I.L. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl. Acad. Sci. USA 2006, 103, 6224–6229.
  38. Laubach, J.P.; Fu, P.; Jiang, X.; Salter, K.H.; Potti, A.; Arcasoy, M.O. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp. Hematol. 2009, 37, 1411–1422.
  39. Walz, C.; Crowley, B.J.; Hudon, H.E.; Gramlich, J.L.; Neuberg, D.S.; Podar, K.; Griffin, J.D.; Sattler, M. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 2006, 281, 18177–18183.
  40. Plo, I.; Nakatake, M.; Malivert, L.; de Villartay, J.P.; Giraudier, S.; Villeval, J.L.; Wiesmuller, L.; Vainchenker, W. JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112, 1402–1412.
  41. Marty, C.; Lacout, C.; Droin, N.; Le Couédic, J.P.; Ribrag, V.; Solary, E.; Vainchenker, W.; Villeval, J.L.; Plo, I. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013, 27, 2187–2195.
  42. Chen, E.; Ahn, J.S.; Massie, C.E.; Clynes, D.; Godfrey, A.L.; Li, J.; Park, H.J.; Nangalia, J.; Silber, Y.; Mullally, A.; et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc. Natl. Acad. Sci. USA 2014, 111, 15190–15195.
  43. Nakatake, M.; Monte-Mor, B.; Debili, N.; Casadevall, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012, 31, 1323–1333.
  44. Silva, M.; Richard, C.; Benito, A.; Sanz, C.; Olalla, I.; Fernández-Luna, J.L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 1998, 338, 564–571.
  45. Zhao, R.; Follows, G.A.; Beer, P.A.; Scott, L.M.; Huntly, B.J.; Green, A.R.; Alexander, D.R. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med. 2008, 359, 2778–2789.
  46. Scherber, R.; Geyer, H.; Dueck, A.; Johnston, C.; Langlais, B.; Padrnos, L.; Palmer, J.; Fleischman, A.; Mesa, R. Nutritional needs and preferences of myeloproliferative neoplasm patients: Phase IA of the Nutrient Study; European Hematology Association Congress: Madrid, Spain, 2017.
  47. Coussens, L.M.; Web, Z. Inflammation and cancer. Nature 2002, 420, 860–867.
  48. Colotta, F.; Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009, 30, 1073–1081.
  49. Marchetti, M.; Ghirardi, A.; Masciulli, A.; Carobbio, A.; Palandri, F.; Vianelli, N.; Rossi, E.; Betti, S.; Di Veroli, A.; Iurlo, A.; et al. Second cancers in MPN: Survival analysis from an international study. Am. J. Hematol. 2020, 95, 295–301.
  50. Pettersson, H.; Knutsen, H.; Holmberg, E.; Andréasson, B. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur. J. Haematol. 2015, 94, 152–156.
  51. Ghirardi, A.; Carobbio, A.; Masciulli, A.; Barbui, T. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer J. 2018, 8, 5.
  52. Hasselbalch, H.C. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015, S0145–S2126, 30373–30378.
  53. Pedersen, K.M.; Bak, M.; Sørensen, A.L.; Zwisler, A.D.; Ellervik, C.; Larsen, M.K.; Hasselbalch, H.C.; Tolstrup, J.S. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. Cancer Med. 2018, 7, 5796–5802.
  54. Hasselbalch, H.C. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012, 119, 3219–3225.
  55. Zhang, C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res. Cardiol. 2008, 103, 398–406.
  56. Folsom, A.R.; Lutsey, P.L.; Astor, B.C.; Cushman, M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009, 102, 615–619.
  57. Di Battista, V.; Bochicchio, M.T.; Giordano, G.; Napolitano, M.; Lucchesi, A. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int. J. Mol. Sci. 2021, 22, 561.
  58. Jelinek, J.; Oki, Y.; Gharibyan, V.; Bueso-Ramos, C.; Prchal, J.T.; Verstovsek, S.; Beran, M.; Estey, E.; Kantarjian, H.M.; Issa, J.P.J. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106, 3370–3373.
  59. Levine, R.L.; Loriaux, M.; Huntly, B.J.; Loh, M.L.; Beran, M.; Stoffregen, E.; Berger, R.; Clark, J.J.; Willis, S.G.; Nguyen, K.T.; et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106, 3377–3379.
  60. Sidon, P.; El Housni, H.; Dessars, B.; Heimann, P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006, 20, 1622.
  61. Klippel, S.; Strunck, E.; Temerinac, S.; Bench, A.J.; Meinhardt, G.; Mohr, U.; Leichtle, R.; Green, A.R.; Griesshammer, M.; Heimpel, H.; et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003, 102, 3569–3574.
  62. Martini, M.; Teofili, L.; Larocca, L.M. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia. Methods Mol. Med. 2006, 125, 265–273.
  63. Bock, O.; Serinsöz, E.; Neusch, M.; Schlué, J.; Kreipe, H. The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders. Br. J. Haematol. 2003, 123, 472–474.
  64. Mirza, A.M.; Correa, P.N.; Axelrad, A.A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood 1995, 86, 877–882.
  65. Wang, J.C.; Shi, G.; Baptiste, S.; Yarotska, M.; Sindhu, H.; Wong, C.; Kalavar, M.; Gotlieb, V.; Bandarchuk, A.; Chen, H. Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion. PLoS ONE 2016, 11, e0165299.
  66. Johansson, P.L.; Safai-Kutti, S.; Kutti, J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br. J. Haematol. 2005, 129, 701–705.
  67. Alvarez-Larrán, A.; Ancochea, A.; Angona, A.; Pedro, C.; García-Pallarols, F.; Martínez-Avilés, L.; Bellosillo, B.; Besses, C. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012, 97, 1704–1707.
  68. Barbui, T.; Thiele, J.; Carobbio, A. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am. J. Hematol. 2014, 89, 199–202.
  69. Barbui, T.; Thiele, J.; Carobbio, A.; Guglielmelli, P.; Rambaldi, A.; Vannucchi, A.M.; Tefferi, A. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am. J. Hematol. 2014, 89, 588–590.
  70. Silver, R.T.; Chow, W.; Orazi, A.; Arles, S.P.; Goldsmith, S.J. Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis. Blood 2013, 122, 1881–1886.
  71. Barbui, T.; Thiele, J.; Gisslinger, H.; Finazzi, G.; Carobbio, A.; Rumi, E.; Luigia Randi, M.; Bertozzi, I.; Vannucchi, A.M.; Pieri, L.; et al. Masked polycythemia vera (mPV): Results of an international study. Am. J. Hematol. 2014, 89, 52–54.
  72. Lussana, F.; Carobbio, A.; Randi, M.L.; Elena, C.; Rumi, E.; Finazzi, G.; Bertozzi, I.; Pieri, L.; Ruggeri, M.; Palandri, F.; et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. Br. J. Haematol. 2014, 167, 541–546.
  73. Song, J.; Hussaini, M.; Zhang, H.; <named-content content-type="background:white">Shao, H.; Qin, D.; Zhang, X.; Ma, Z.; Hussnain Naqvi, S.M.; Zhang, L.; Moscinski, L.C. Comparison of the mutational profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am. J. Clin. Pathol. 2017, 147, 444–452.
  74. Goerttler, P.S.; Kreutz, C.; Donauer, J.; Faller, D.; Maiwald, T.; März, E.; Rumberger, B.; Sparna, T.; Schmitt-Gräff, A.; Wilpert, J.; et al. Gene expression profiling in polycythaemia vera: Overexpression of transcription factor NF-E2. Br. J. Haematol. 2005, 129, 138–150.
  75. Gallardo, M.; Barrio, S.; Fernandez, M.; Paradela, A.; Arenas, A.; Toldos, O.; Ayala, R.; Albizua, E.; Jimenez, A.; Redondo, S.; et al. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Mol. Cancer 2013, 12, 142.
  76. Brusson, M.; Cochet, S.; Leduc, M.; Guillonneau, F.; Mayeux, P.; Peyrard, T.; Chomienne, C.; Le Van Kim, C.; Cassinat, B.; Kiladjian, J.J.; et al. Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation. Haematologica 2017, 102, e241–e244.
  77. Bruchova, H.; Merkerova, M.; Prchal, J.T. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008, 93, 1009–1016.
  78. Zhan, H.; Cardozo, C.; Yu, W.; Wang, A.; Moliterno, A.R.; Dang, C.V.; Spivak, J.L. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol. Dis. 2013, 50, 190–195.
  79. Campbell, P.J.; Scott, L.M.; Buck, G.; Wheatley, K.; East, C.L.; Marsden, J.T.; Duffy, A.; Boyd, E.M.; Bench, A.J.; Scott, M.A.; et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005, 366, 1945–1953.
  80. Passamonti, F.; Rumi, E.; Pietra, D.; Della Porta, M.G.; Boveri, E.; Pascutto, C.; Vanelli, L.; Arcaini, L.; Burcheri, S.; Malcovati, L.; et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107, 3676–3682.
  81. Alshemmari, S.H.; Rajaan, R.; Ameen, R.; Al-Drees, M.A.; Almosailleakh, M.R. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann. Hematol. 2014, 93, 791–796.
  82. Grinfeld, J.; Nangalia, J.; Baxter, E.J.; Wedge, D.C.; Angelopoulos, N.; Cantrill, R.; Godfrey, A.L.; Papaemmanuil, E.; Gundem, G.; MacLean, C.; et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N. Engl. J. Med. 2018, 379, 1416–1430.
  83. Tiedt, R.; Hao-Shen, H.; Sobas, M.A.; Looser, R.; Dirnhofer, S.; Schwaller, J.; Skoda, R.C. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111, 3931–3940.
  84. Li, J.; Kent, D.G.; Godfrey, A.L.; Manning, H.; Nangalia, J.; Aziz, A.; Chen, E.; Saeb-Parsy, K.; Fink, J.; Sneade, R.; et al. JAK2V617FJAK2V617F homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain disease. Blood 2014, 123, 3139–3151.
  85. Chaiter, Y.; Brenner, B.; Aghai, E.; Tatarsky, I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992, 7, 251–255.
  86. Landgren, O.; Goldin, L.R.; Kristinsson, S.Y.; Helgadottir, E.A.; Samuelsson, J.; Bjorkholm, M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood 2008, 112, 2199–2204.
  87. Rumi, E.; Passamonti, F.; Della Porta, M.G.; Elena, C.; Arcaini, L.; Vanelli, L.; Del Curto, C.; Pietra, D.; Boveri, E.; Pascutto, C.; et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J. Clin. Oncol. 2007, 25, 5630–5635.
  88. Jones, A.V.; Chase, A.; Silver, R.T.; Oscier, D.; Zoi, K.; Wang, Y.L.; Cario, H.; Pahl, H.L.; Collins, A.; Reiter, A.; et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41, 446–449.
  89. Olcaydu, D.; Harutyunyan, A.; Jäger, R.; Berg, T.; Gisslinger, B.; Pabinger, I.; Gisslinger, H.; Kralovics, R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 2009, 41, 450–454.
  90. Kilpivaara, O.; Mukherjee, S.; Schram, A.M.; Wadleigh, M.; Mullally, A.; Ebert, B.L.; Bass, A.; Marubayashi, S.; Heguy, A.; Garcia-Manero, G.; et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)- positive myeloproliferative neoplasms. Nat. Genet. 2009, 41, 455–459.
  91. Olcaydu, D.; Skoda, R.C.; Looser, R.; Li, S.; Cazzola, M.; Pietra, D.; Passamonti, F.; Lippert, E.; Carillo, S.; Girodon, F.; et al. The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 2009, 23, 1924–1926.
  92. Nussenzveig, R.H.; Swierczek, S.I.; Jelinek, J.; Gaikwad, A.; Liu, E.; Verstovsek, S.; Prchal, J.F.; Prchal, J.T. Polycythemia vera is not initiated by JAK2V617F mutation. Exp. Hematol. 2007, 35, 32–38.
  93. Kralovics, R.; Teo, S.S.; Li, S.; Theocharides, A.; Buser, A.S.; Tichelli, A.; Skoda, R.C. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108, 1377–1380.
  94. Rumi, E.; Passamonti, F.; Pietra, D.; Della Porta, M.G.; Arcaini, L.; Boggi, S.; Elena, C.; Boveri, E.; Pascutto, C.; Lazzarino, M.; et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006, 107, 2206–2211.
  95. James, C. The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases? Hematology Am. Soc. Hematol. Educ. Program. 2008, 2008, 69–75.
  96. Lanikova, L.; Babosova, O.; Swierczek, S.; Wang, L.; Wheeler, D.A.; Divoky, V.; Korinek, V.; Prchal, J.T. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera. Blood 2016, 128, 2266–2270.
  97. Harutyunyan, A.S.; Giambruno, R.; Krendl, C.; Stukalov, A.; Klampfl, T.; Berg, T.; Milosevic, J.D.; Chen, D.; Gisslinger, B.; Gisslinger, H.; et al. Germline RBBP6 Mutations In Myeloproliferative Neoplasms [abstract]. Blood 2013, 122, 267.
  98. Oddsson, A.; Kristinsson, S.Y.; Helgason, H.; Gudbjartsson, D.F.; Masson, G.; Sigurdsson, A.; Jonasdottir, A.; Jonasdottir, A.; Steingrimsdottir, H.; Vidarsson, B.; et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia 2014, 28, 1371–1374.
  99. Harutyunyan, A.S.; Giambruno, R.; Krendl, C.; Stukalov, A.; Klampfl, T.; Berg, T.; Chen, D.; Milosevic Feenstra, J.D.; Jäger, R.; Gisslinger, B.; et al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood 2016, 127, 362–365.
  100. Bao, E.L.; Nandakumar, S.K.; Liao, X.; Bick, A.G.; Karjalainen, J.; Tabaka, M.; Gan, O.I.; Havulinna, A.S.; Kiiskinen, T.; Lareau, C.A.; et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature 2020, 586, 769–775.
  101. Giaccherini, M.; Macauda, A.; Sgherza, N.; Sainz, J.; Gemignani, F.; Maldonado, J.; Jurado, M.; Tavano, F.; Mazur, G.; Jerez, A.; et al. Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. Blood Cancer J. 2020, 10, 89.
  102. Williams, N.; Lee, J.; Moore, L.; Baxter, J.E.; Hewinson, J.; Dawson, K.J.; Menzies, A.; Godfrey, A.L.; Green, A.R.; Campbell, P.J.; et al. Driver mutation acquisition in utero and childhood followed by lifelong clonal evolution underlie myeloproliferative neoplasms. 2020 ASH Annual Meeting & Exposition. Abstract LBA-1. Presented December 8, 2020. Available online: (accessed on 15 February 2021).
  103. Nangalia, J.; Green, T.R. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am. Soc. Hematol. Educ. Program. 2014, 2014, 287–296.
  104. Tefferi, A.; Lasho, T.L.; Guglielmelli, P.; Finke, C.M.; Rotunno, G.; Elala, Y.; Pacilli, A.; Hanson, C.A.; Pancrazzi, A.; Ketterling, R.P.; et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016, 1, 21–30.
  105. Segura-Díaz, A.; Stuckey, R.; Florido, Y.; González-Martín, J.M.; López-Rodríguez, J.F.; Sánchez-Sosa, S.; González-Pérez, E.; Sáez Perdomo, M.N.; Perera, M.; de la Iglesia, S.; et al. Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations. Cancers 2020, 12, 934.
  106. Green, A.; Beer, P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med. 2010, 362, 369–370.
  107. Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.; et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18, 553–567.
  108. Marcault, C.; Zhao, L.P.; Daltro De Oliveira, R.; Soret, J.; Gauthier, N.; Verger, E.; Maslah, N.; Roux, B.; Parquet, N.; Dosquet, C.; et al. NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN). Blood 2020, 136 (Suppl. 1), 36.
  109. Marinaccio, C.; Suraneni, P.K.; Celik, H.; Volk, A.; Wen, J.Q.; Ling, T.; Lasho, T.; Koche, R.P.; Famulare, C.; Stein, B.L.; et al. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. Blood 2020, 136 (Suppl. 1), 1.
  110. Laurie, C.C.; Laurie, C.A.; Rice, K.; Doheny, K.F.; Zelnick, L.R.; McHugh, C.P.; Ling, H.; Hetrick, K.N.; Pugh, E.W.; Amos, C.; et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat. Genet. 2012, 44, 642–650.
  111. Busque, L.; Patel, J.P.; Figueroa, M.E.; Vasanthakumar, A.; Provost, S.; Hamilou, Z.; Mollica, L.; Li, J.; Viale, A.; Heguy, A.; et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 2012, 44, 1179–1181.
  112. Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.; Burtt, N.; Chavezet, A.; et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 2014, 371, 2488–2498.
  113. Genovese, G.; Kähler, A.K.; Handsaker, R.E.; Lindberg, J.; Rose, S.A.; Bakhoum, S.F.; Chambert, K.; Mick, E.; Neale, B.M.; Fromer, M.; et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014, 371, 2477–2487.
  114. Xie, M.; Lu, C.; Wang, J.; McLellan, M.D.; Johnson, K.J.; Wendl, M.C.; McMichael, J.F.; Schmidt, H.K.; Yellapantula, V.; Miller, C.A.; et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 2014, 20, 1472–1478.
  115. Steensma, D.P.; Bejar, R.; Jaiswal, S.; Lindsley, C.; Sekeres, M.A.; Hasserjian, R.P.; Ebert, B.L. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015, 126, 9–16.
  116. Jaiswal, S.; Natarajan, P.; Silver, A.J.; Gibson, C.J.; Bick, A.G.; Shvartz, E.; McConkey, M.; Gupta, N.; Gabriel, S.; Ardissino, D.; et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 2017, 377, 111–121.
  117. Tefferi, A.; Pardanani, A.; Lim, K.H.; Abdel-Wahab, O.; Lasho, T.L.; Patel, J.; Gangat, N.; Finke, C.M.; Schwager, S.; Mullally, A.; et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23, 905–911.
  118. Delhommeau, F.; Dupont, S.; Della Valle, V.; James, C.; Trannoy, S.; Massé, A.; Kosmider, O.; Le Couedic, J.P.; Robert, F.; Alberdi, A.; et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360, 2289–2301.
  119. Kameda, T.; Shide, K.; Yamaji, T.; Kamiunten, A.; Sekine, M.; Taniguchi, Y.; Hidaka, T.; Kubuki, Y.; Shimoda, H.; Marutsuka, K.; et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: Disease sustainer and disease accelerator. Blood 2015, 125, 304–315.
  120. Chen, E.; Schneider, R.K.; Breyfogle, L.J.; Rosen, E.A.; Poveromo, L.; Elf, S.; Ko, A.; Brumme, K.; Levine, R.; Ebert, B.L.; et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 2015, 125, 327–335.
  121. Hughes, A.E.; Magrini, V.; Demeter, R.; Miller, C.A.; Fulton, R.; Fulton, L.L.; Eades, W.C.; Elliott, K.; Heath, S.; Westervelt, P.; et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 2014, 10, e1004462.
  122. Nice, F.L.; Massie, C.E.; Klampfl, T.; Green, A.R. Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies. Exp. Hematol. 2018, 57, 60–64.
  123. Yang, L.; Rau, R.; Goodell, M.A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 2015, 15, 152–165.
  124. Ortmann, C.A.; Kent, D.G.; Nangalia, J.; Silber, Y.; Wedge, D.C.; Grinfeld, J.; Baxter, E.J.; Massie, C.E.; Papaemmanuil, E.; Menon, S.; et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 2015, 372, 601–612.
  125. Tefferi, A.; Guglielmelli, P.; Larson, D.R.; Finke, C.; Wassie, E.A.; Pieri, L.; Gangat, N.; Fjerza, R.; Belachew, A.A.; Lasho, T.L.; et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014, 124, 2507–2513.
  126. McMullin, M.F.; Bareford, D.; Campbell, P.; Green, A.R.; Harrison, C.; Hunt, B.; Oscier, D.; Polkey, M.I.; Reilly, J.T.; Rosenthal, E.; et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br. J. Haematol. 2005, 130, 174–195.
  127. Tefferi, A.; Guglielmelli, P.; Lasho, T.L.; Coltro, G.; Finke, C.M.; Loscocco, G.G.; Sordi, B.; Szuber, N.; Rotunno, G.; Pacilli, A.; et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br. J. Haematol. 2020, 189, 291–302.
  128. Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Rambaldi, A.; Barosi, G.; Marchioli, R.; Marfisi, R.M.; Finazzi, G.; Guerini, V.; Fabris, F.; et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110, 840–846.
  129. Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Longo, G.; Pancrazzi, A.; Ponziani, V.; Bogani, C.; Ferrini, P.R.; Rambaldi, A.; Guerini, V.; et al. MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21, 1952–1959.
  130. Gangat, N.; Strand, J.J.; Lasho, T.L.; Li, C.Y.; Pardanani, A.; Tefferi, A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am. J. Hematol. 2008, 83, 451–453.
  131. Larsen, T.S.; Pallisgaard, N.; Møller, M.B.; Hasselbalch, H.C. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur. J. Haematol. 2007, 79, 508–515.
  132. Kirschner, M.M.; Schemionek, M.; Schubert, C.; Chatain, N.; Sontag, S.; Isfort, S.; Ortiz-Brüchle, N.; Schmitt, K.; Krüger, L.; Zerres, K.; et al. Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS ONE 2015, 10, e0123476.
  133. Borowczyk, M.; Wojtaszewska, M.; Lewandowski, K.; Gil, L.; Lewandowska, M.; Lehmann-Kopydłowska, A.; Kroll-Balcerzak, R.; Balcerzak, A.; Iwoła, M.; Michalak, M.; et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 2015, 135, 272–280.
  134. Malak, S.; Labopin, M.; Saint-Martin, C.; Bellanne-Chantelot, C.; Najman, A.; French Group of Familial Myeloproliferative Disorders. Long term follow up of 93 families with myeloproliferative neoplasms: Life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol. Dis. 2012, 49, 170–176.
  135. Kralovics, R.; Teo, S.S.; Buser, A.S.; Brutsche, M.; Tiedt, R.; Tichelli, A.; Passamonti, F.; Pietra, D.; Cazzola, M.; Skoda, R.C. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005, 106, 3374–3376.
  136. Vainchenker, W.; Constantinescu, S.N. A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases. Hematology Am. Soc. Hematol. Educ. Program. 2005, 195–200.
  137. Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Pardanani, A.; Tefferi, A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 2008, 22, 1299–1307.
  138. Vannucchi, A.M.; Antonioli, E.; Guglielmeli, P.; Pancrazzi, A.; Bogani, C.; Pieri, L.; Bosi, A. Influence of the JAK2V617F mutational load at diagnosis on major clinical aspects in patients with Polycythemia vera. Blood 2006, 108, 5.
  139. Vannucchi, A.M.; Barosi, G.; Rimbaldi, A.; Barosi, G.; Rambaldi, A.; Marchioli, R.; Barbui, T.; Gimema, W.P. Clinical significance of JAK2V617F homozygosity in the chronic myeloproliferative disorders. A study of 1306 patients. Blood 2006, 108, 664.
  140. Spivak, J.L.; Considine, M.; Williams, D.M.; Talbot, C.C., Jr.; Rogers, O.; Moliterno, A.R.; Jie, C.; Ochs, M.F. Two clinical phenotypes in polycythemia vera. N. Engl. J. Med. 2014, 371, 808–817.
  141. Swolin, B.; Weinfeld, A.; Westin, J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988, 72, 386–395.
  142. Diez-Martin, J.L.; Graham, D.L.; Petitt, R.M.; Dewald, G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin. Proc. 1991, 66, 287–299.
  143. Gangat, N.; Strand, J.; Lasho, T.L.; Finke, C.M.; Knudson, R.A.; Pardanani, A.; Li, C.Y.; Ketterling, R.P.; Tefferi, A. Cytogenetic studies at diagnosis in polycythemia vera: Clinical and JAK2V617F allele burden correlates. Eur. J. Haematol. 2008, 80, 197–200.
  144. Finazzi, F.; Caruso, V.; Marchioli, R.; Capnist, G.; Chisesi, T.; Finelli, C.; Gugliotta, L.; Landolfi, R.; Kutti, J.; Gisslinger, H.; et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 2005, 105, 2664–2670.
  145. Tang, G.; Hidalgo Lopez, J.E.; Wang, S.A.; Hu, S.; Ma, J.; Pierce, S.; Zuo, W.; Carballo-Zarate, A.A.; Yin, C.C.; Tang, Z.; et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 2017, 102, 1511–1518.
  146. Sever, M.; Quintás-Cardama, A.; Pierce, S.; Zhou, L.; Kantarjian, H.; Verstovsek, S. Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma 2013, 54, 2667–2670.
  147. Tefferi, A.; Rumi, E.; Finazzi, G.; Gisslinger, H.; Vannucchi, A.M.; Rodeghiero, F.; Randi, M.L.; Vaidya, R.; Cazzola, M.; Rambaldi, A.; et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013, 27, 1874–1881.
  148. Cerquozzi, S.; Tefferi, A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors. Blood Cancer J. 2015, 5, e366.
  149. Barbui, T.; Vannucchi, A.M.; Carobbio, A.; Thiele, J.; Rumi, E.; Gisslinger, H.; Rodeghiero, F.; Randi, M.L.; Rambaldi, A.; Pieri, L.; et al. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. Am. J. Hematol. 2015, 90, 434–437.
  150. Barbui, T.; Barosi, G.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Griesshammer, M.; Harrison, C.; Hasselbalch, H.C.; Hehlmann, R.; Hoffman, R.; et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol. 2011, 29, 761–770.
  151. Vannucchi, A.M. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr. Hematol. Malig Rep. 2010, 5, 22–28.
  152. Chia, Y.C.; Islam, M.A.; Woon, P.Y.; Johan, M.F.; Hassan, R.; Ramli, M. Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology. Genes Dis. 2021.
  153. Ruggeri, M.; Gisslinger, H.; Tosetto, A.; Rintelen, C.; Mannhalter, C.; Pabinger, I.; Heis, N.; Castaman, G.; Missiaglia, E.; Lechner, K.; et al. Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am. J. Hematol. 2002, 71, 1–6.
  154. Jensen, M.K.; de Nully Brown, P.; Thorsen, S.; Hasselbalch, H.C. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am. J. Hematol. 2002, 69, 185–191.
  155. Trifa, A.P.; Cucuianu, A.; Popp, R.A.; Coadă, C.A.; Costache, R.M.; Militaru, M.S.; Vesa, S.C.; Pop, I.V. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. Ann. Hematol. 2014, 93, 203–209.
  156. Algahtani, F.H.; Stuckey, R. High factor VIII levels and arterial thrombosis: Illustrative case and literature review. Ther. Adv. Hematol. 2019, 10, 2040620719886685.
  157. Sacco, M.; Ranalli, P.; Lancellotti, S.; Petrucci, G.; Dragani, A.; Rocca, B.; De Cristofaro, R. Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Res. Pract Thromb Haemost. 2020, 4, 413–421.
  158. De Stefano, V.; Za, T.; Rossi, E.; Vannucchi, A.M.; Ruggeri, M.; Elli, E.; Micò, C.; Tieghi, A.; Cacciola, R.R.; Santoro, C.; et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am. J. Hematol. 2010, 85, 97–100.
  159. Carobbio, A.; Ferrari, A.; Masciulli, A.; Ghirardi, A.; Barosi, G.; Barbui, T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: A systematic review and meta-analysis. Blood Adv. 2019, 3, 1729–1737.
  160. Barbui, T.; Finazzi, G.; Carobbio, A.; Thiele, J.; Passamonti, F.; Rumi, E.; Ruggeri, M.; Rodeghiero, F.; Randi, M.L.; Bertozzi, I.; et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012, 120, 5128–5133.
  161. Carobbio, A.; Finazzi, G.; Antonioli, E.; Guglielmelli, P.; Vannucchi, A.M.; Dellacasa, C.M.; Salmoiraghi, S.; Delaini, F.; Rambaldi, A.; Barbui, T. JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Exp. Hematol. 2009, 37, 1016–1021.
  162. Horvat, I.; Boban, A.; Zadro, R.; Antolic, M.R.; Serventi-Seiwerth, R.; Roncevic, P.; Radman, I.; Sertic, D.; Vodanovic, M.; Pulanic, D.; et al. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Clin. Lymphoma Myeloma Leuk 2019, 19, 53–63.
  163. Barbui, T.; Carobbio, A.; Finazzi, G.; Vannucchi, A.M.; Barosi, G.; Antonioli, E.; Guglielmelli, P.; Pancrazzi, A.; Salmoiraghi, S.; Zilio, P.; et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3. Haematologica 2011, 96, 315–318.
  164. Fuster, J.J.; MacLauchlan, S. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017, 355, 842–847.
  165. Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Libby, P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1b inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J. 2019, 41, 2153–2163.
  166. CARDIoGRAMplusC4D Consortium; Deloukas, P.; Kanoni, S.; Willenborg, C.; Farrall, M.; Assimes, T.L.; Thompson, J.R.; Ingelsson, E.; Saleheen, D.; Erdmann, J.; et al. Large--scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 2013, 45, 25–33.
  167. Wang, W.; Tang, Y.; Wang, Y.; Tascau, L.; Balcerek, J.; Tong, W.; Levine, R.L.; Welch, C.; Tall, A.R.; Wang, N. LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. Circ Res. 2016, 119, e91–e103.
  168. Kaplar, J.K.; Kiss, A.K.; Szabo, M.; Udvardy, M. Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts. Platelets 2000, 11, 183–184.
  169. Jensen, M.K.; de Nully Brown, P.; Lund, B.V.; Nielsen, O.J.; Hasselbalch, H.C. Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur. J. Haematol. 2001, 66, 143–151.
  170. Griesshammer, M.; Klippel, S.; Strunck, E.; Temerinac, S.; Mohr, U.; Heimpel, H.; Pahl, H.L. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann. Hematol. 2004, 83, 364–370.
  171. Shahrabi, S.; Ehsanpour, A.; Heidary, S.; Shahjahani, M.; Behzad, M.M. Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance. Oncol. Rev. 2018, 12, 373.
  172. Ferrer-Marín, F.; Cuenca-Zamora, E.J.; Guijarro-Carrillo, P.J.; Teruel-Montoya, R. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms. Int. J. Mol. Sci. 2021, 22, 1143.
  173. Ma, X.; Vanasse, G.; Cartmel, B.; Wang, Y.; Selinger, H.A. Prevalence of polycythemia vera and essential thrombocythemia. Am. J. Hematol. 2008, 83, 359–362.
  174. Benton, C.B.; Tanaka, M.; Wilson, C.; Pierce, S.; Zhou, L.; Cortes, J.; Kantarjian, H.; Verstovsek, S. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015, 39, 419–423.
  175. Harutyunyan, A.; Klampfl, T.; Cazzola, M.; Kralovics, R. p53 lesions in leukemic transformation. N. Engl. J. Med. 2011, 364, 488–490.
  176. Rotunno, G.; Pacilli, A.; Artusi, V.; Rumi, E.; Maffioli, M.; Delaini, F.; Brogi, G.; Fanelli, T.; Pancrazzi, A.; Pietra, D.; et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Am. J. Hematol. 2016, 91, 681–686.
  177. Vannucchi, A.M.; Lasho, T.L.; Guglielmelli, P.; Biamonte, F.; Pardanani, A.; Pereira, A.; Finke, C.; Score, J.; Gangat, N.; Mannarelli, C.; et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27, 1861–1869.
  178. Gowin, K.; Coakley, M.; Kosiorek, H.; Mesa, R. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis. Haematologica 2016, 101, e405–e406.
  179. Passamonti, F.; Giorgino, T.; Mora, B.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017, 31, 2726–2731.
  180. Palandri, F.; Palumbo, G.A.; Iurlo, A.; Polverelli, N.; Benevolo, G.; Breccia, M.; Abruzzese, E.; Tiribelli, M.; Bonifacio, M.; Tieghi, A.; et al. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. Semin Hematol. 2018, 55, 248–255.
  181. Mora, B.; Giorgino, T.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J.J.; et al. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project. Haematologica 2018, 103, e392–e394.
  182. Theocharides, A.; Boissinot, M.; Girodon, F.; Garand, R.; Teo, S.S.; Lippert, E.; Talmant, P.; Tichelli, A.; Hermouet, S.; Skoda, R.C. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110, 375–379.
  183. Beer, P.A.; Delhommeau, F.; LeCouédic, J.P.; Dawson, M.A.; Chen, E.; Bareford, D.; Kusec, R.; McMullin, M.F.; Harrison, C.N.; Vannucchi, A.M.; et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115, 2891–2900.
  184. Lundberg, P.; Karow, A.; Nienhold, R.; Looser, R.; Hao-Shen, H.; Nissen, I.; Girsberger, S.; Lehmann, T.; Passweg, J.; Stern, M.; et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014, 123, 2220–2228.
  185. Luque Paz, D.; Jouanneau-Courville, R.; Riou, J.; Ianotto, J.C.; Boyer, F.; Chauveau, A.; Renard, M.; Chomel, J.C.; Cayssials, E.; Gallego-Hernanz, M.P.; et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: Genomic profiles predict time to transformation. Blood Adv. 2020, 4, 4887–4897.
  186. Rampal, R.; Ahn, J.; Abdel-Wahab, O.; Nahas, M.; Wang, K.; Lipson, D.; Otto, G.A.; Yelensky, R.; Hricik, T.; McKenney, A.S.; et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc. Natl. Acad. Sci. USA 2014, 111, E5401–E5410.
  187. Senín, A.; Fernández-Rodríguez, C.; Bellosillo, B.; Camacho, L.; Longarón, R.; Angona, A.; Besses, C.; Álvarez-Larrán, A. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann. Hematol. 2018, 97, 443–451.
  188. Abdel-Wahab, O.; Manshouri, T.; Patel, J.; Harris, K.; Yao, J.; Hedvat, C.; Heguy, A.; Bueso-Ramos, C.; Kantarjian, H.; Levine, R.L.; et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010, 70, 447–452.
  189. Spivak, J.L. How I treat polycythemia vera. Blood 2019, 134, 341–352.
  190. Antonioli, E.; Guglielmelli, P.; Pieri, L.; Finazzi, M.; Rumi, E.; Martinelli, V.; Vianelli, N.; Luigia Randi, M.; Bertozzi, I.; De Stefano, V.; et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am. J. Hematol. 2012, 87, 552–554.
  191. Alvarez-Larrán, A.; Kerguelen, A.; Hernández-Boluda, J.C.; Pérez-Encinas, M.; Ferrer-Marín, F.; Bárez, A.; Martínez-López, J.; Cuevas, B.; Mata, M.I.; García-Gutiérrez, V.; et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br. J. Haematol. 2016, 172, 786–793.
  192. Alvarez-Larrán, A.; Díaz-González, A.; Such, E.; Mora, E.; Andrade-Campos, M.; García-Hernández, C.; Gómez-Casares, M.T.; García-Gutiérrez, V.; Carreño-Tarragona, G.; Garrote, M.; et al. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia 2021, 35, 623–627.
  193. Bose, P.; Verstovsek, S. JAK2 inhibitors for myeloproliferative neoplasms: What is next? Blood 2017, 130, 115–125.
  194. Vannucchi, A.M.; Kiladjian, J.J.; Griesshammer, M.; Masszi, T.; Durrant, S.; Passamonti, F.; Harrison, C.N.; Pane, F.; Zachee, P.; Mesa, R.; et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 2015, 372, 426–435.
  195. Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P.J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C.; et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014, 120, 513–520.
  196. Passamonti, F.; Griesshammer, M.; Palandri, F.; Egyed, M.; Benevolo, G.; Devos, T.; Callum, J.; Vannucchi, A.M.; Sivgin, S.; Bensasson, C.; et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study. Lancet Oncol. 2017, 18, 88–99.
  197. Verstovsek, S.; Courby, S.; Griesshammer, M.; Mesa, R.A.; Brachmann, C.B.; Kawashima, J.; Maltzman, J.D.; Shao, L.; Xin, Y.; Huang, D.; et al. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017, 60, 11–17.
  198. Samuelson, B.T.; Vesely, S.K.; Chai-Adisaksopha, C.; Scott, B.L.; Crowther, M.; Garcia, D. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: A meta-analysis. Blood Coagul Fibrinolysis 2016, 27, 648–652.
  199. Besremi: EPAR—Public Assessment report., European Medicines Agency, December 2018. Available online: (accessed on 25 February 2021).
  200. Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Rossiev, V.; Dulicek, P.; Illes, A.; Pylypenko, H.; et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020, 7, e196–e208.
  201. Barbui, T.; Vannucchi, A.M.; De Stefano, V.; Masciulli, A.; Carobbio, A.; Ferrari, A.; Ghirardi, A.; Rossi, E.; Ciceri, F.; Bonifacio, M.; et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): A multicentre, randomised phase 2 trial. Lancet Haematol. 2021, 8, e175–e184.
  202. de Weerd, N.A.; Nguyen, T. The interferons and their receptors--distribution and regulation. Immunol. Cell Biol. 2012, 90, 483–491.
  203. Chawla-Sarkar, M.; Lindner, D.J.; Liu, Y.-F.; Williams, B.R.; Sen, G.C.; Silverman, R.H.; Borden, E.C. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8, 237–249.
  204. Hansen, I.O.; Sørensen, A.L.; Hasselbalch, H.C. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur. J. Haematol. 2017, 98, 75–84.
  205. Faille, D.; Lamrani, L.; Loyau, S.; Huisse, M.-G.; Bourrienne, M.-C.; Alkhaier, S.; Cassinat, B.; Boulaftali, Y.; Debus, J.; Jandrot-Perrus, M.; et al. Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms. Cancers 2020, 12, 992.
  206. Iurlo, A.; Cattaneo, D.; Bucelli, C.; Baldini, L. New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. Int. J. Mol. Sci. 2020, 21, 5805.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback